2023
Vigorous Exercise in Patients With Hypertrophic Cardiomyopathy
Lampert R, Ackerman M, Marino B, Burg M, Ainsworth B, Salberg L, Tome Esteban M, Ho C, Abraham R, Balaji S, Barth C, Berul C, Bos M, Cannom D, Choudhury L, Concannon M, Cooper R, Czosek R, Dubin A, Dziura J, Eidem B, Emery M, Estes N, Etheridge S, Geske J, Gray B, Hall K, Harmon K, James C, Lal A, Law I, Li F, Link M, McKenna W, Molossi S, Olshansky B, Ommen S, Saarel E, Saberi S, Simone L, Tomaselli G, Ware J, Zipes D, Day S, Abrahms D, Ashley E, Aziz P, Batra A, Cerrone M, Colan S, Erickson C, Ferhaan A, Gollob M, Johnsrude C, Kannankeril P, Kanter R, Li W, Masri A, Murphy A, Nandi D, Perez M, Perry J, Popjes E, Rao R, Rosenthal D, Sanatani S, Semsarian C, Shah M, Skinner J, Tardif J, Towbin J, Turer A, Webster G, Wever-Pinzon O, Wong T. Vigorous Exercise in Patients With Hypertrophic Cardiomyopathy. JAMA Cardiology 2023, 8: 595-605. PMID: 37195701, PMCID: PMC10193262, DOI: 10.1001/jamacardio.2023.1042.Peer-Reviewed Original ResearchMeSH KeywordsArrhythmias, CardiacCardiomyopathy, HypertrophicCohort StudiesExerciseHeart ArrestHumansMaleProspective StudiesConceptsComposite end pointVigorous-intensity exerciseHypertrophic cardiomyopathyVigorous exerciseEnd pointCohort studyExercise categoriesVentricular arrhythmiasPhysical activityPrimary composite end pointMultivariate Cox regression analysisAdjusted hazard ratioProspective cohort studyCox regression analysisLeft ventricular hypertrophyLife-threatening arrhythmiasSudden cardiac arrestImplantable cardioverter defibrillatorHigh rateHCM centersNonvigorous activitiesObservational registryAppropriate shocksExperienced centersHazard ratio
2019
Baseline Characteristics of the VANISH Cohort
Axelsson Raja A, Shi L, Day SM, Russell M, Zahka K, Lever H, Colan SD, Margossian R, Hall EK, Becker J, Jefferies JL, Patel AR, Choudhury L, Murphy AM, Canter C, Bach R, Taylor M, Mestroni L, Wheeler MT, Benson L, Owens AT, Rossano J, Lin KY, Pahl E, Pereira AC, Bundgaard H, Lewis GD, Vargas JD, Cirino AL, McMurray JJV, MacRae CA, Solomon SD, Orav EJ, Braunwald E, Ho CY. Baseline Characteristics of the VANISH Cohort. Circulation Heart Failure 2019, 12: e006231. PMID: 31813281, PMCID: PMC7219518, DOI: 10.1161/circheartfailure.119.006231.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAngiotensin II Type 1 Receptor BlockersBrazilCanadaCardiomyopathy, HypertrophicChildDenmarkDisease ProgressionDouble-Blind MethodFemaleGenetic Predisposition to DiseaseHumansMaleMiddle AgedMutationPhenotypeRecovery of FunctionSarcomeresTime FactorsTreatment OutcomeUnited StatesValsartanYoung AdultConceptsAngiotensin receptor blockersHypertrophic cardiomyopathyReceptor blockersBaseline characteristicsImaging abnormalitiesPrimary cohortMutation carriersNew York Heart Association class IINew York Heart Association classFunctional class II symptomsOlder ageClass II symptomsNonobstructive hypertrophic cardiomyopathyNormal functional capacityPrevious trialsVentricular wall thicknessPeak oxygen consumptionPlacebo-controlled designCardiac magnetic resonanceGene mutation carriersLate gadolinium enhancementVANISH trialAdvanced diseaseAssociation classVentricular hypertrophy